FDA Efforts Trans Fat and Salt Julie Moss

FDA Efforts: Trans Fat and Salt Julie Moss, Ph. D, RD Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Nutrition, Labeling and Dietary Supplements

Trans Fat 2006 Requires a trans fat amount without a %DV Incentive for industry to decrease the trans fat content of foods

Trans Fat: ANPRM 2003 Claims n n n (68 FR 41507; July 11, 2003) Disqualifying/disclosure levels Coincide with saturated fat limits? New trans fat claims Possible footnote/disclosure statement DV n n format method for determination Consumer Research

Trans Fat: ANPRM 2007 (72 FR 62149; November 2, 2007) Goal: Update daily values and mandatory nutrients Questions from the 2003 ANPRM are being asked again regarding a DV so these issues can be considered in the context of the entire Nutrition Facts and Supplement Facts labels Comments accepted until April 30, 2008

Trans Fat Consumer Research Data is collected, analysis to follow: n n n Evaluating consumer understanding of varying product characteristics (sat fat and cholesterol levels) having trans “free” and “reduced” nutrient content claims Evaluating consumer understanding of various footnote options (e. g. , Intake of trans fat should be kept low) Evaluating effectiveness of various DV formats (trans fat DV combined with saturated fat, no trans fat DV)

Trans Fat Analysis GC methods: FDA, AOCS and commercial labs to look at detection limits Will know more later this Spring

Trans Fat Analysis IR methods: 1. Qualitative id at low levels (0. 5% total fat) • • Anal Bioanal Chem (2007) 389: 87– 92 J Amer Oil Chem Soc (2007) 84: 339– 342 2. Develop improved method to quantify low levels (below 0. 5 g/serving) • To be published 3. Validation study through international labs • Australia, Switzerland, Germany, Canada, China, US

Next Steps for Trans Fat Use… ANPRM Comments Science Consumer Research …to develop a strategy to determine further rulemaking for trans fat labeling, e. g. , claims, disqualifying/disclosure levels, DV or footnote statement

Salt: Labeling Nutrient content claims (free, low, lightly salted, healthy, etc. ) Health claims n n Low sodium & BP Good K, Low NA & BP/stroke Disclosure/disqualifying criteria Nutrition Facts label with a DV

Salt: ANPRM 2007 (72 FR 62149; November 2, 2007) Should the DRV for sodium be based on the UL for sodium (2, 300 mg/day) as suggested by the Dietary Guidelines for Americans or should it be based on the AI (1, 500 mg/d using the population-coverage approach)? If the UL should be used, should it be adjusted using the same approach (population-weighted or population-coverage) as the other DRIs? Comments accepted until April 30, 2008

Salt: GRAS Salt is regulated as a GRAS ingredient per 21 CFR 182. 1 FDA has commented previously on salt’s GRAS status and has chosen labeling, rather than ingredient regulation, to encourage lower sodium intakes (per 1982 Policy Notice).

Salt: Public Hearing November 29, 2007 Goal n n Re-examine FDA’s current framework of policies regarding salt and Na Discuss potential, future approaches as requested in a petition from CSPI Information and comments accepted until March 28, 2008

Next Steps for Salt Reviewing comments to ANPRM on updating the daily values for labeling Reviewing information and comments from the public hearing n Respond to the petition from CSPI

THANK YOU Trans Fat or Labeling: Julie. Moss@fda. hhs. gov Salt: Richard. Bonnette@fda. hhs. gov